Latest Stories
Uncategorized
Takeda Signs Up to $1.7 Billion AI Deal With Iambic Therapeutics for Small-Molecule Drug Design
Takeda signed a multi-year AI drug discovery collaboration with Iambic Therapeutics worth up to $1.7 billion in milestones, giving Takeda access to Iambic's NeuralPLexer protein-ligand prediction model for small-molecule programs in oncology and inflammatory disease.
Uncategorized
FDA Seeks Public Comment on Regulating Generative AI Medical Devices as Cleared AI Tools Top 700
The FDA's Digital Health Center of Excellence opened a public comment period, closing October 19, on a discussion paper proposing a risk-proportionate framework for regulating generative AI medical devices.
Uncategorized
GSK Widens AI Drug Design Deal With Chai Discovery After In-House Scientists Validate Its Models
GSK expanded its collaboration with Chai Discovery in October after its own scientists independently tested and validated the AI startup's molecular design models, a notable vote of confidence in Chai's approach.
Uncategorized
VA Awards Abridge a Multi-Year AI Scribe Contract Worth Up to $775.72 Million Across Vendors
The Department of Veterans Affairs has selected Abridge for an enterprise-wide ambient AI scribe contract with a five-year ceiling of $775.72 million across all eligible vendors, expanding a technology already deployed at roughly 70 VA medical centers.
In-Depth
Uncategorized
OpenAI Wires ChatGPT Into Epic’s Electronic Health Records in Push Toward Clinical Workflows
OpenAI announced on September 1 that ChatGPT for Healthcare now connects directly to Epic's electronic health record system, with UCSF Health piloting the read-only integration alongside a new plugin linking ChatGPT to nine public health databases.
Uncategorized
Sanofi Licenses AI-Designed mRNA Platform From ScionxBio in New Drug Development Bet
Sanofi has entered a worldwide strategic licensing agreement with ScionxBio to access an AI-designed mRNA technology platform, extending the AI drug discovery wave into messenger RNA therapeutics.
Uncategorized
AstraZeneca Partners With Tremont AI to Screen Drug Candidates for Toxicity Before Human Trials
AstraZeneca is working with startup Tremont AI to build AI models that flag potentially toxic drug candidates earlier in development, aiming to cut the cost and time lost to late-stage trial failures.
Uncategorized
Tempus AI’s $1.5 Billion Bid for Personalis Heads to a Shareholder Vote
Personalis shareholders of record as of October 15 will soon vote on Tempus AI's all-stock acquisition, a deal that would fold Personalis' cancer genomics testing into Tempus' AI-driven oncology data platform.
Uncategorized
AI Primary Care Study Finds Zero Safety Stops Across 114 Patients
A Lancet-published study of an AI system handling direct patient interactions in primary care reported no safety-related stops across 114 patients, a notable milestone for AI deployed in frontline clinical settings.
